We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Neonatal Saliva Enables Ultrasensitive Detection of Sepsis-Associated Proteins

By LabMedica International staff writers
Posted on 21 Jan 2025
Print article
Image: Schematic of a salivary Simoa assay (Photo courtesy of Rolando, J. (2025); doi.org/10.1038/s44328-025-00026-1)
Image: Schematic of a salivary Simoa assay (Photo courtesy of Rolando, J. (2025); doi.org/10.1038/s44328-025-00026-1)

Sepsis is a critical condition that affects millions of newborns each year. Current diagnostic procedures involve painful, repetitive blood collections to isolate and culture the microorganism responsible for the infection. Results can take up to five days to return, potentially exposing newborns to unnecessary antibiotic treatments. Developing a quicker, non-invasive method to assess infectious status based on the host's immune response offers a promising alternative for infection screening. However, additional blood collection to multiplex inflammatory biomarkers in neonates remains impractical. Saliva, though difficult to work with due to much lower protein concentrations (100 to 1000 times less than blood), could provide an alternative biofluid for testing. To overcome this challenge, researchers have developed a set of six ultra-sensitive single-molecule array (Simoa) assays that can detect inflammatory biomarkers linked to neonatal sepsis even in small amounts of saliva.

This panel of six Simoa assays was developed through a collaborative effort between investigators at the University of California, San Francisco (UCSF, San Francisco, CA, USA). The inflammatory biomarkers associated with neonatal sepsis include serum amyloid A1 (SAA1), lipopolysaccharide-binding protein (LBP), chemokines CCL20, CXCL6, CXCL12, and the adipokine resistin. Using the Simoa platform, the research team demonstrated that these biomarkers could be detected in neonatal saliva. The study showed that salivary biomarkers CCL20 and CXCL6 were significantly elevated in neonates with infections and sepsis compared to uninfected ones, indicating their potential for use in neonatal infection screening.

The study, published in npj Biosensing, is the first to show that chemokines, adipokines, and acute phase reactants can be measured in neonatal saliva. The small saliva volumes (~10 μL) and low concentrations of these biomarkers (pg/mL) highlight the need for ultra-sensitive assays in developing non-invasive diagnostics. This work reinforces the value of neonatal saliva as a viable sample for infection monitoring. The researchers believe that these assays could be utilized in future diagnostic tests to distinguish between infected and uninfected neonates. Advancing salivary-based diagnostics for neonatal conditions is a significant step toward reducing the risks associated with blood draws and improving care for this vulnerable group. While these assays represent a crucial first step for diagnosing neonatal sepsis, they will require further validation to ensure consistency and reliability.

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Human Cytomegalovirus Test
HCMV Real Time PCR Kit
New
Silver Member
CEA Assay
Carcinoembryonic Antigen Assay

Print article

Channels

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Pathology

view channel
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)

Revolutionary AI Tool Transforms Disease Visualization

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. Occasionally, alterations in these instructions—known as mutations—can interfere... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.